ADPT
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp (ADPT) has 27 SEC Form 4 filings (135 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Jul 7, 2026.
The most active filer is President and COO RUBINSTEIN JULIE with 28 filings. Insiders have net sold $29.6M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Chad Robins
- Employees:619
- HQ:Seattle, WA, US
- IPO:2019-06-27
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$44.8M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Market Cap
$3.4B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Scientific Officer | Sale | 386,240 | $8.5M | Jul 7 | SEC ↗ | |
| Chief People Officer | Sale | 51,004 | $1.1M | Jul 6 | SEC ↗ | |
| Chief People Officer | Sale | 44,838 | $1.0M | Jul 6 | SEC ↗ | |
| Chief Commercial Officer, MRD | Sale | 487 | $11K | Jul 6 | SEC ↗ | |
BENZENO SHARONFirst in 7 months | Chief Commercial Ofc Imm Med | Sale | 11,034 | $232K | Jun 30 | SEC ↗ |
BENZENO SHARONFirst in 7 months | Chief Commercial Ofc Imm Med | Sale | 154,768 | $3.3M | Jun 30 | SEC ↗ |
| Chief Commercial Officer, MRD | Sale | 5,000 | $103K | Jun 29 | SEC ↗ | |
GRIFFIN MICHELLE RENEEFirst filing | Director | Sale | 52,084 | $1.1M | Jun 29 | SEC ↗ |
ROBINS HARLAN SFirst filing | Chief Scientific Officer | Sale | 100,000 | $1.7M | Jun 17 | SEC ↗ |
ROBINS HARLAN SFirst filing | Chief Scientific Officer | Sale | 6,160 | $111K | Jun 17 | SEC ↗ |
| Chief Commercial Officer, MRD | Sale | 5,000 | $95K | Jun 15 | SEC ↗ | |
LO FRANCISFirst in 5 months | Chief People Officer | Sale | 39,741 | $695K | Jun 9 | SEC ↗ |
BOBULSKY SUSANFirst filing | Chief Commercial Officer, MRD | Sale | 11,000 | $198K | Jun 9 | SEC ↗ |
PISKEL KYLEFirst in 6 months | Chief Financial Officer | Sale | 3,115 | $41K | May 20 | SEC ↗ |
| President and COO | Sale | 19,037 | $271K | Apr 29 | SEC ↗ | |
| President and COO | Sale | 19,060 | $269K | Apr 24 | SEC ↗ | |
| President and COO | Sale | 19,060 | $262K | Apr 24 | SEC ↗ | |
| President and COO | Sale | 19,060 | $267K | Apr 24 | SEC ↗ | |
| President and COO | Sale | 19,060 | $278K | Apr 21 | SEC ↗ | |
| President and COO | Sale | 19,060 | $277K | Apr 21 | SEC ↗ | |
| President and COO | Sale | 30,941 | $454K | Apr 21 | SEC ↗ | |
| President and COO | Sale | 19,060 | $264K | Apr 13 | SEC ↗ | |
| President and COO | Sale | 19,060 | $243K | Apr 13 | SEC ↗ | |
| President and COO | Sale | 19,060 | $251K | Apr 13 | SEC ↗ | |
| President and COO | Sale | 19,060 | $273K | Apr 8 | SEC ↗ | |
| President and COO | Sale | 19,060 | $258K | Apr 8 | SEC ↗ | |
| President and COO | Sale | 30,941 | $459K | Apr 8 | SEC ↗ | |
| President and COO | Sale | 19,060 | $261K | Mar 26 | SEC ↗ | |
| President and COO | Sale | 19,060 | $272K | Mar 26 | SEC ↗ | |
| President and COO | Sale | 19,060 | $269K | Mar 26 | SEC ↗ | |
| President and COO | Sale | 19,060 | $251K | Mar 23 | SEC ↗ | |
| President and COO | Sale | 19,060 | $255K | Mar 23 | SEC ↗ | |
| President and COO | Sale | 19,060 | $264K | Mar 23 | SEC ↗ | |
| President and COO | Sale | 19,060 | $256K | Mar 18 | SEC ↗ | |
| President and COO | Sale | 19,060 | $255K | Mar 18 | SEC ↗ | |
| President and COO | Sale | 19,060 | $251K | Mar 18 | SEC ↗ | |
| President and COO | Sale | 141,583 | $1.9M | Mar 13 | SEC ↗ | |
| President and COO | Sale | 19,060 | $245K | Mar 13 | SEC ↗ | |
| President and COO | Sale | 19,060 | $247K | Mar 13 | SEC ↗ | |
RUBINSTEIN JULIEFirst filing | President and COO | Sale | 30,941 | $485K | Mar 5 | SEC ↗ |
RUBINSTEIN JULIEFirst filing | President and COO | Sale | 30,941 | $514K | Mar 5 | SEC ↗ |
RUBINSTEIN JULIEFirst filing | President and COO | Sale | 30,941 | $495K | Mar 5 | SEC ↗ |
| Chief People Officer | Sale | 79,590 | $1.4M | Jan 14 | SEC ↗ | |
| Chief People Officer | Sale | 4,394 | $77K | Jan 7 | SEC ↗ | |
LO FRANCISFirst filing | Chief People Officer | Sale | 113,890 | $1.8M | Dec 17 | SEC ↗ |
PISKEL KYLEFirst filing | Chief Financial Officer | Sale | 162,820 | $3.2M | Dec 2 | SEC ↗ |
BENZENO SHARONFirst filing | Chief Commercial Ofc Imm Med | Sale | 297,925 | $4.9M | Nov 24 | SEC ↗ |
BENZENO SHARONFirst filing | Chief Commercial Ofc Imm Med | Sale | 308,477 | $5.2M | Nov 24 | SEC ↗ |
Related companies
Adaptive Biotechnologies Corp is in the Healthcare sector.